Focus: Rallybio is a publicly traded oncology-focused biotechnology company headquartered in New Haven, CT, currently in early-stage clinical development with minimal revenue generation.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Rallybio to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Rallybio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rallybio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Avenzo Therapeutics Merges With Rallybio To Advance Oncology Portfolio - HarianBasis.co
Avenzo Therapeutics Merges With Rallybio To Advance Oncology Portfolio HarianBasis.co
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of GlobeNewswire
After failed deal, Rallybio announces new merger; New Haven HQ to close - Hartford Business Journal
After failed deal, Rallybio announces new merger; New Haven HQ to close Hartford Business Journal
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio Pharmaceutical Executive
Rallybio swerves past Candid pothole to land deal with Avenzo - Fierce Biotech
Rallybio swerves past Candid pothole to land deal with Avenzo Fierce Biotech
RallyBio tries again for reverse merger, this time with Avenzo - BioPharma Dive
RallyBio tries again for reverse merger, this time with Avenzo BioPharma Dive
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo